Circulating eosinophils associated with responsiveness to COVID-19 vaccine and the disease severity in patients with SARS-CoV-2 omicron variant infection

[1]  Haijun Huang,et al.  Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China , 2022, Advanced Gut & Microbiome Research.

[2]  Yuxin Chen,et al.  The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants , 2022, Emerging microbes & infections.

[3]  Graham W. Taylor,et al.  Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England , 2022, Science.

[4]  M. Diamond,et al.  Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2 , 2022, Nature.

[5]  A. Ariel,et al.  Weathering the Storm: Harnessing the Resolution of Inflammation to Limit COVID-19 Pathogenesis , 2022, Frontiers in Immunology.

[6]  W. Marasco,et al.  Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants , 2022, eBioMedicine.

[7]  Rui Qiao,et al.  Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages , 2022, Cell Host & Microbe.

[8]  M. Tobin,et al.  Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis , 2022, PLoS medicine.

[9]  B. Baradaran,et al.  Inflammatory reflex disruption in COVID‐19 , 2022, Clinical & experimental neuroimmunology.

[10]  T. Zhou,et al.  Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2 , 2022, Cell Host & Microbe.

[11]  Ö. Türeci,et al.  The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines , 2022, mBio.

[12]  E. Rubin,et al.  Audio Interview: Understanding the Omicron Variant of SARS-CoV-2. , 2022, New England Journal of Medicine.

[13]  B. Walker,et al.  T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals , 2022, Cell.

[14]  T. Luetkens,et al.  Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine , 2022, Clinical & translational immunology.

[15]  V. Ortega,et al.  Eosinophilia Is Associated with Improved COVID-19 Outcomes in Inhaled Corticosteroid-Treated Patients , 2022, The Journal of Allergy and Clinical Immunology: In Practice.

[16]  D. Stravopodis,et al.  Prediction of SARS-CoV-2 Omicron Variant Immunogenicity, Immune Escape and Pathogenicity, through the Analysis of Spike Protein-Specific Core Unique Peptides , 2021, medRxiv.

[17]  Cdc Covid- Response Team.  SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[18]  S. le Cessie,et al.  Coronavirus disease 2019 and peripheral blood eosinophil counts: a retrospective study , 2021, Infection.

[19]  A. Hashmi,et al.  COVID-19 in older adults. , 2021, Cleveland Clinic journal of medicine.

[20]  S. Ohde,et al.  Visual classification of three computed tomography lung patterns to predict prognosis of COVID-19: a retrospective study , 2021, BMC Pulmonary Medicine.

[21]  Yixiao Lin,et al.  Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection , 2021, Clinical & translational immunology.

[22]  J. Sastre,et al.  Eosinophils and Chronic Respiratory Diseases in Hospitalized COVID-19 Patients , 2021, Frontiers in Immunology.

[23]  G. Guyatt,et al.  A living WHO guideline on drugs to prevent covid-19 , 2021, BMJ.

[24]  Hongzhou Lu,et al.  An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 , 2020, EClinicalMedicine.

[25]  Hongzhou Lu,et al.  The role of peripheral blood eosinophil counts in COVID‐19 patients , 2020, Allergy.

[26]  M. Djalali,et al.  Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies , 2020, The aging male : the official journal of the International Society for the Study of the Aging Male.

[27]  Ling Ye,et al.  Assessing risk factors for SARS-CoV-2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort study , 2020, The Lancet Digital Health.

[28]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[29]  W. Liang,et al.  Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China , 2020, Chest.

[30]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[31]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[32]  Q. Pham,et al.  Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam , 2020, The New England journal of medicine.

[33]  J. Routy,et al.  Aging of immune system: Immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults , 2016, Aging.

[34]  W. Bergamaschi,et al.  Boosters and time from the last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment. , 2022, Epidemiologia & Prevenzione.

[35]  OUP accepted manuscript , 2022, Age and Ageing.